viewSareum Holdings PLC

Sareum expects to complete at least one pre-clinical trial this year


  • Lead drug being developed by partner Sierra Oncology
  • Encouraging preliminary efficacy data on SRA737 
  • Has other preclinical treatments - one autoimmune disease, one for cancer

Quick facts: Sareum Holdings PLC

Price: 0.92 GBX

Market: AIM
Market Cap: £29.95 m


We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.

Dr Tim Mitchell, chief executive


About Sareum

Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology

The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.



This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage

It is currently undergoing two Phase II clinical trials in patients with advanced cancer – one as a monotherapy and another in combination with low-dose gemcitabine, which is one of the most commonly commonly-prescribed chemotherapies.

Preliminary efficacy data from a phase I/II clinical trial carried out by Vancouver-based Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties, was encouraging.  

Most eye-catching among the headlines was the impact SRA737 had in harness with gemcitabine in patients with anogenital cancer, where the response rate was 30%.

New research in March also highlighted the therapeutic potential of SRA737 in a new drug combination targeting lung and colorectal cancers published in Cancer Research, a leading peer-reviewed journal



What else is in the pipeline

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation.

In March, it entered into an agreement with a China-based speciality pharmaceutical company to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including Sareum's lead candidate SAR-20293.

In June, the company raised £718,500 before expenses via a placing of shares at 0.6p each with the new funds used to explore the potential benefit of its TYK2/JAK1 inhibitors against coronavirus (COVID-19).

A separate fundraiser overseen by PrimaryBid will offer private investors new shares in the company on the same terms.

As at March 31, 2020, Sareum had cash of £980,000. It expects to receive a research and development tax credit next January of £150,000.


What the boss says: Tim Mitchell, CEO (June)  

WSareum continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802.

“We are targeting the completion of at least one preclinical study in the fourth quarter and are developing our plans for the initial clinical trials with both compounds,


Inflexion points 

  • Commercial licences for the late pre-clinical or early clinical stages of SDC 1801/1802
  • Sierra Oncology raises funds for development of SRA737
  • Raised £7i8,000 in June


Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 30/6/20

3 min read